• In early August 2026, Amdocs cut its full‑year GAAP EPS outlook to a decline of 5.0% to 3.0% while slightly narrowing revenue growth guidance, even as it affirmed a US$0.569 quarterly dividend and completed a US$440.6 million buyback covering 5.77% of its shares.
• At the same time, Amdocs is leaning into agentic AI and automation across its BSS/OSS platforms, aiming to reposition itself as an AI-powered operations partner for telecom and enterprise customers.
• With weaker earnings guidance but continued dividends and buybacks, we'll examine how Amdocs' push into agentic AI reshapes its investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Amdocs Investment Narrative Recap

To own Amdocs, you have to believe telecom and enterprise customers will keep relying on its software and services even as they experiment with newer AI tools. The sharp cut to full year GAAP EPS guidance highlights earnings volatility as the biggest near term risk, while adoption of its agentic AI offerings remains the key catalyst investors are watching. This guidance reset is material for short term sentiment around execution and profit quality.

The most relevant update is the revised full year 2026 outlook, which now calls for GAAP EPS to decline 5.0% to 3.0% and slightly tighter revenue growth of 3.2% to 4.0%. Set against that, Amdocs kept its US$0.569 dividend and completed a US$440.6 million buyback, suggesting capital returns are continuing even as earnings soften, which matters for anyone weighing the risk that weaker customer spending or slower AI monetization could pressure results further.

Yet investors should be aware that if telco cloud and AI projects are phased more cautiously than expected, it could...

Amdocs' narrative projects $5.2 billion revenue and $832.7 million earnings by 2029. This requires 4.0% yearly revenue growth and an earnings increase of about $286.9 million from $545.8 million today.

Uncover how Amdocs' forecasts yield a $81.21 fair value, a 38% upside to its current price.

Exploring Other Perspectives

The lowest analyst estimates tell a much more cautious story, even before this guidance cut. They were assuming only about 4.1% annual revenue growth and US$845.9 million of earnings by 2029, so this kind of EPS reset could easily push them toward an even more pessimistic view of how quickly Amdocs’ AI and transformation work translate into profits.

Explore 6 other fair value estimates on Amdocs - why the stock might be worth just $70.84!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amdocs research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amdocs research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amdocs' overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.